← Eichor
Study identifier: NCT05161702 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).

Condition: Resolution of Inflammation · Reduction of Cell Proliferation  ·  Sponsor: SCF Pharma

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride omega-3 fatty acids on the resolution of inflammation.

This description comes directly from the study's public registry record.

Talk to the study team

Samuel Fortin, PhD  ·  418-750-8590  ·  sfortin@scfpharma.com

Anne-Julie Landry, M.Sc  ·  ajlandry@scfpharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

SCF PharmaRimouski, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05161702